Discovery of a novel class of selective human CB1 inverse agonists

Nicolas Foloppe; Nicola H Allen; Carol H Bentley; Teresa D Brooks; Guy Kennett; Antony R Knight; Stefania Leonardi; Anil Misra; Nathaniel J T Monck; Daniel M Sellwood

doi:10.1016/j.bmcl.2007.11.133

Discovery of a novel class of selective human CB1 inverse agonists

Bioorg Med Chem Lett. 2008 Feb 1;18(3):1199-206. doi: 10.1016/j.bmcl.2007.11.133. Epub 2007 Dec 7.

Authors

Nicolas Foloppe¹, Nicola H Allen, Carol H Bentley, Teresa D Brooks, Guy Kennett, Antony R Knight, Stefania Leonardi, Anil Misra, Nathaniel J T Monck, Daniel M Sellwood

Affiliation

¹ Vernalis (R&D) Ltd, Granta Park, Abington, Cambridge CB21 6GB, UK. n.foloppe@vernalis.com

PMID: 18083560
DOI: 10.1016/j.bmcl.2007.11.133

Abstract

Ligand-based virtual screening led to the discovery of a new class of potent inverse agonists of the human cannabinoid receptor 1, hCB(1), which are selective versus hCB(2). These CB(1) ligands present intriguing departures from a classical CB(1) antagonist pharmacophore. Elements of SAR are discussed in this context.

MeSH terms

Cannabinoids / chemical synthesis*
Cannabinoids / chemistry
Cannabinoids / pharmacology*
Combinatorial Chemistry Techniques
Drug Design
Humans
Ligands
Molecular Structure
Receptor, Cannabinoid, CB1 / agonists*
Receptor, Cannabinoid, CB2 / agonists
Structure-Activity Relationship

Substances

Cannabinoids
Ligands
Receptor, Cannabinoid, CB1
Receptor, Cannabinoid, CB2